Cannabix Technologies Makes Advances with Marijuana Breathalyzer Development and THC Breath Capture
July 15 2019 - 9:20AM
Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (the
“Company” or “Cannabix”) developer of the Cannabix Marijuana
Breathalyzer for law enforcement and the workplace, is pleased to
report that Company scientists have made significant advancements
with analyte in breath capture and FAIMS cell development.
Cannabix scientists have been optimizing the breath / sample
capture procedures and technology to maximize
∆9-tetrahydrocannabinol (“THC”) analyte capture from human breath.
THC is found in breath in generally low quantities. The Company has
significantly improved sample collection methods using the breath
collection unit (“BCU”) and other newly developed techniques.
In addition, engineers have developed a proprietary next generation
FAIMS cell that is currently being tested. The Company has been
steadily progressing with human breath testing at its Vancouver,
BC, based lab with its FAIMS (field asymmetric waveform ion
mobility spectrometry) THC detection device and BCU.
Comment on Saliva Testing
“We would like to make it clear that roadside saliva tests are
not “breathalyzers” and do not represent the promise of breath
testing for roadside marijuana impairment. It is apparent that
existing saliva-testing devices are being used in some
jurisdictions because no regulatory evidential breath testing
devices currently exist on the market. Cannabix and our product
development work is dedicated to the development of marijuana
breathalyzer technologies. Saliva testing, also known as “oral swab
testing” is not new technology and has been available for many
years. There are well documented issues with saliva testing
including its ability to effectively identify impaired individuals
and operate in cold weather conditions, to name a few. There are a
growing number of examples of the lack of confidence in saliva
testing devices. In 2018, Vermont Senate Judiciary Committee
rejected a bill authorizing the use of saliva testing in traffic
enforcement, amid concerns of scientific validity, accuracy, and
infringement on civil liberties. In 2019, a Nova Scotia woman
initiated the first court challenge in Canada related to saliva
testing, where she claims she tested positive for THC, several
hours after she used medical marijuana. Most police detachments
have not adopted saliva testing to date, opting for better
technology options that are being developed.
Cannabix believes that an accurate evidential breath testing
device for THC is the future for law enforcement and workplace
testing, as it is less invasive and will look to provide superior
method to better determine impairment. It is well documented that
breath is a better indicator of impairment than saliva, blood, or
urine because THC only remains in breath for short period of time
(2-3 hours) before becoming virtually undetectable, whereas it can
remain in other body fluids for many hours, days, or even weeks
after smoking. This short time period of detection in breath aligns
with the peak impairment window.
The Company has received significant interest for its technology
from police and companies in the U.S., Canada and elsewhere.
As the issue of drugged driving becomes increasingly acute,
Cannabix is committed to using its technology, R&D and
scientific experience to provide effective tools to aid law
enforcement and help governments and the public transition to
marijuana legalization in various jurisdictions. Cannabix is a well
funded Canadian company that is rapidly developing its marijuana
breathalyzer technology.”
About Cannabix Technologies Inc.
Cannabix Technologies Inc. is a leader in marijuana breathalyzer
development for law enforcement and the workplace. Cannabix has
established breath testing technologies in the pursuit of bringing
durable, portable hand-held tools to market to enhance detection of
marijuana impaired driving offences on roads at a time when
marijuana is becoming legal in many global jurisdictions. Cannabix
is working to develop drug-testing devices that will detect THC-
the psychoactive component of marijuana that causes intoxication-
using breath samples. In particular, Cannabix is focused on
developing breath testing devices for detection of recent use of
THC, in contrast to urine testing for THC metabolite that requires
an invasive collection and reflects usage, days or even weeks
earlier. The devices will also be useful for other practical
applications such as testing employees in the workplace where
impairment by THC can be hazardous.
We seek Safe Harbor. On behalf of the Board of
Directors
“Rav Mlait”
CEOCannabix Technologies Inc.
For further information, contact the Company
at info@cannabixtechnologies.com
The CSE has not reviewed and does not accept responsibility for
the adequacy or accuracy of this release.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking information that
involves various risks and uncertainties regarding future events.
Such forward-looking information can include without limitation
statements based on current expectations involving a number of
risks and uncertainties and are not guarantees of future
performance of the Company, such as final development of a
commercial or prototype product(s), successful trial or pilot of
company technologies, no assurance that commercial sales of any
kind actually materialize; no assurance the Company will have
sufficient funds to complete product development. There are
numerous risks and uncertainties that could cause actual results
and the Company’s plans and objectives to differ materially from
those expressed in the forward-looking information, including: (i)
adverse market conditions; (ii) risks regarding protection of
proprietary technology; (iii) the ability of the Company to
complete financings; (iv) the ability of the Company to develop and
market its future product; and (v) risks regarding government
regulation, managing and maintaining growth, the effect of adverse
publicity, litigation, competition and other factors which may be
identified from time to time in the Company's public announcements
and filings. There is no assurance that the marijuana breathalyzer
business will provide any benefit to the Company, and no assurance
that any proposed new products will be built or proceed. There is
no assurance that existing “patent pending” technologies licensed
by the Company will receive patent status by regulatory
authorities. The Company is not currently selling commercial
breathalyzers. Actual results and future events could differ
materially from those anticipated in such information. These and
all subsequent written and oral forward-looking information are
based on estimates and opinions of management on the dates they are
made and are expressly qualified in their entirety by this notice.
Except as required by law, the Company does not intend to update
these forward-looking statements.
Cannabix Technologies (CSE:BLO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cannabix Technologies (CSE:BLO)
Historical Stock Chart
From Sep 2023 to Sep 2024